Foresee Pharmaceuticals Announces Publication of Preclinical Data in Nature Communications Demonstrating the Therapeutic Potential of ALDH2 Activator AD-9308 in the Treatment of Obesity and Metabolic Syndrome-Related Disorders

AD-9308 is a potent, and highly selective oral ALDH2 activator ready for IND-enabling development. AD-9308 treatment ameliorates diet-induced obesity and fatty liver, and improves glucose homeostasis in both male Aldh2 wild-type and Aldh2*2 knock-in mice. A first-in-class oral ALDH2…